Healthcare Technology Consultant/Contributing Writer
Keith Speights is a healthcare technology consultant and contributing writer for various publications, including The Motley Fool and Yahoo Finance. With a focus on financial analysis and investment strategies, Keith provides insights into stock market trends, retirement planning, and social security changes that impact millions of Americans. His work has been featured in USA TODAY, Nasdaq, and other reputable news outlets.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Keith Speights focuses on investment analysis, particularly in the stock market and personal finance, with a heavy emphasis on healthcare and pharmaceuticals. He cites data significantly in his articles.
When reaching out to Keith, consider offering insights or analyses related to investing strategies, dividend stocks, social security issues, retirement planning tips or developments in the healthcare and pharmaceutical sectors. Additionally, providing data-driven perspectives would likely resonate well with him given his frequent citation of data in his coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Keith Speights
Key Points The most bought stock by members of Congress last year was an oil stock -- but not Chevron or ExxonMobil. Lawmakers could have been attracted by the stock's low valuation and high dividend yield. The stock appears to be a good pick now with the potential for oil prices to rise. 10 stocks we like better than ConocoPhillips
By: Keith Speights
These stocks could be near major inflection points.
By: Keith Speights
Key Points Ackman, Coleman, and Tepper have different investing styles, but they all like one AI leader. This company's competitive advantages include making its own AI chips and access to cloud processing. The stock could face pressure over the near term but looks to be a great long-term pick. Motley Fool Issues Rare “All In” Buy Alert
By: Keith Speights
Key Points The 2025 Social Security COLA won't be announced until mid-October, but inflation trends could help predict what it might be. There are different ways to project next year's COLA -- none of which are perfect. A lot can happen between now and October. Motley Fool Issues Rare “All In” Buy Alert
By: Keith Speights
Key Points Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy. Vertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market. Viking Therapeutics has key potential catalysts coming soon for its promising NASH and X-ALD therapies. Motley Fool Issues Rare “All In” Buy Alert
By: Keith Speights
Key Points More lawmakers traded these stocks than any others over the last three years. The list includes big winners such as Microsoft and Nvidia. It also includes big losers such as AT&T, Verizon, and PayPal. 10 stocks we like better than Amazon
Key Points Amazon's growth drivers include advertising, cloud services, and a new satellite internet service. Intel could gain market share with its new AI chips. Salesforce's transformation initiative is paying off in increased productivity and profits. Motley Fool Issues Rare “All In” Buy Alert
Key Points Bristol Myers Squibb beat Wall Street estimates in the first quarter. However, the company slashed its full-year earnings outlook because of recent acquisitions and collaborations. The big drugmaker faces patent expirations for some of its top-selling drugs over the next few years. Motley Fool Issues Rare “All In” Buy Alert
By: Keith Speights
Key Points Ken Griffin aggressively added to his hedge fund's stakes in three "Magnificent Seven" stocks in Q4. It's easy to guess why the billionaire investor likes these three stocks. The current pullbacks for these stocks could present great buying opportunities. Motley Fool Issues Rare “All In” Buy Alert
By: Keith Speights
Can Bitcoin keep up its winning ways?
(833) 317-6278 
